Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Mescaline/Equity and Ethics

Mescaline for Equity and Ethics

3 papers and 0 clinical trials exploring mescaline as a treatment for equity and ethics.

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
IndicationApproximately 1 in 4 adults experience mental health disorders annually worldwide.

Equity and Ethics

Equity and ethics in psychedelic research is a vital and complex topic, addressing the need for fair access and representation in clinical trials, as well as the stewardship of traditional knowledge. The involvement of Indigenous communities, who have historically used these substances, must be safeguarded against exploitation as the field matures.

Full Equity and Ethics profile

Academic Research

3 papers
Paywallindividual

Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension

Using nationally representative NSDUH data (2015–2019, N = 211,549), the study found lifetime psilocybin use was associated with lowered odds of several types of past-year arrests (adjusted ORs 0.30–0.73). Peyote and mescaline showed limited protective associations for specific offences, most other substances were unrelated or linked to higher arrest odds, and causality remains unestablished.

Published
January 28, 2022
Journal
Journal of Psychopharmacology
Authors
Jones, G. M., Nock, M. K.
Paywallmeta

Research abuses against people of colour and other vulnerable groups in early psychedelic research

This review of early psychedelic studies (the 50s-70s, s=48) finds that most (77%) would not pass ethical review today. The errors made in early research were extensive dosing, lack of consent, inadequate setting, and lack of scientific hypotheses. The authors make restorative justice and cultural competency suggestions.

Published
July 12, 2021
Journal
Journal of Medical Ethics
Authors
Strauss, D., de la Salle, S., Sloshower, J. A., Williams, M. T.
Paywallindividual

Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species

This mouse study investigates the correlation between the hallucinogens potency in the mouse head-twitch response (HTR) paradigm and their reported potencies in other species such as rats and humans. It used dose-response studies with psychedelics in mice and found a very strong correlation (r=0.95) with earlier human data (n=36).

Published
May 1, 2020
Journal
Neuropharmacology
Authors
Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., Brandt, S. D.

Clinical Trials

0 trials

No clinical trials have been tagged with both Mescaline and Equity and Ethics yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Mescaline papers Search all Equity and Ethics trials Full Mescaline profile Full Equity and Ethics profile